| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3824749 | Progrès en Urologie | 2013 | 8 Pages |
Abstract
In our experience, Hexvix® targeting was associated with better diagnosis for bladder cancer with 9% (13/144) of new positive samples (PÂ =Â 0.003). In our study, false positive rate is a critical point (53.4%). Multifocality, previous TCC, and EORTC score for recurrence and progression might allow selecting patients to be targeted by Hexvix®.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
A. Ferré, C. Cordonnier, M. Demailly, F. Hakami, H. Sevestre, F. Saint,